Medicine Overview

Indication

Know Medicine, Follow Guideline

Adult Dose

Clinical InformationAdministration Information
Indication: Rheumatoid Arthritis
Age: Adult
Condition: moderately-to-severely active rheumatoid arthritis in combination with methotrexate
Dose: Subcutaneous solution – 50 mg
Frequency: once monthly
Note: in combination with methotrexate
Indication: Rheumatoid Arthritis
Age: Adult
Condition: moderately-to-severely active rheumatoid arthritis in combination with methotrexate
Dose: Intravenous solution – 2 mg/kg
Frequency: at weeks 0 and 4, then every 8 weeks
Note: in combination with methotrexate

Child Dose

Clinical InformationAdministration Information
Indication: Moderately to severely active ulcerative colitis
Age: 2 years of age and older
Dose: Subcutaneous injection – 200 mg at Week 0, then 100 mg at Week 2, Week 6 and every 4 weeks thereafter
Frequency: Every 4 weeks after induction
Note: Subcutaneous injection
Indication: Moderately to severely active ulcerative colitis
Age: 2 years of age and older
Dose: Subcutaneous injection – 100 mg at Week 0, then 50 mg at Week 2, Week 6 and every 4 weeks thereafter
Frequency: Every 4 weeks after induction
Note: Subcutaneous injection

Renal Dose

Clinical InformationAdministration Information
Condition: Renal impairment
Dose: Not specified
Note: No formal trial of the effect of renal or hepatic impairment on pharmacokinetics was conducted
Administration
  • For SC injection or IV infusion
  • Allow to reach room temperature before use
Side Effect

Drug Interaction

Drug NameRisk Factors
Abatacept, anakinra, rituximab
Increased infection risk
Live-virus vaccines
May decrease humoral response

Disease Interaction

Disease NameRisk Factors
No specific contraindications listed
Monitor for general drug reactions

Pregnancy

Lactation
Special Use
Precaution
Overdose
Pharmacology
Storage
Golimumab must be refrigerated at 2ºC to 8ºC and protected from light. Keep the product in the original carton to protect from light until the time of use. Do not freeze. Do not shake

Data Sources

Clinical & regulatory information on this page is compiled from the following government sources:

DISCLAIMER: This drug information content is provided for informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Patients should always consult their physician with any questions regarding a medical condition and to obtain medical advice and treatment.